Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
Localized prostate cancer genotyping: another step towards personalized therapy
Poor survival with high-dose chemotherapy and autologous stem cell support in double-hit and double-expressor B-cell lymphomas
Facing pseudoprogression after radiotherapy in low grade gliomas
Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer?
Osimertinib in advanced EGFR T790M-positive non-small-cell lung cancer: the clinical impact of AURA3
Low-frequency ultrasound may improve drug penetration in colonic mucosa
IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm
Relevance of the Hedgehog pathway in T-cell acute lymphoblastic leukemia
A story of ALK variants and the efficacy of ALK inhibitors: moving toward precision oncology
NLRC3 mediated PI3K-mTOR inhibition takes a toll on colon cancer
Lessons from the NOVA trial: an editorial on results, biomarkers, and patient selection for PARP inhibition in recurrent ovarian cancer
Immunotherapy’s new challenge: identification of predictive biomarkers for tumor response
Exploring gold nanoparticle interactions with proteins and the tumor microenvironment in biological systems
Postoperative seizure control in glioma patients with epilepsy
Normalizing tumoral vessels to treat cancer: an out-of-the-box strategy involving TIE2 pathway
Rogue one: another faction of the Wnt empire implicated in assisting GBM progression
The emerging role of Interleukin-21 as an antineoplastic immunomodulatory treatment option
Current and emerging perspectives on immunotherapy for pancreatic cancer
Glioma-associated epilepsy: toward mechanism-based treatment
Transient receptor potential, Melastatin-2 (TRPM2) blockade: perspectives on potential novel clinical utility in cancer
Development of predictive liquid biomarkers for response to treatment in small cell lung cancer
Circulating tumor cells as a liquid biopsy in small cell lung cancer, a future editorial
Uncertainties of cumulative dose assessment for prostate IMRT
Adjuvant therapy in renal-cell carcinoma: Is it prime time yet?
TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
KDM1 links nuclear GSK3β to epigenetic alterations
Dividing and conquering the variation among variants in EML4-ALK lung cancer
Will PI3K-targeted therapies for cancer become a reality?
Editorial to “Palbociclib and letrozole in advanced breast cancer”
Brigatinib and the new generation of ALK-inhibitors for non-small cell lung cancer
Unlocking the epigenetic code of T cell exhaustion
The CXCL12/CXCR4 pathway or the autocrine proliferative loop of the glioblastoma stem cells
Genomic mutational profiles of metastatic breast cancer: obtaining them early and during the continuum of oncological care
TRPV1: a channel for mammalian sperm thermotaxis?
New insights into human testicular germ cell tumors: miR-223-3p gains oncogene function
Quantification of PD-L1 expression in non-small cell lung cancer
Translating prognostic prostate cancer gene signatures into the clinic
Subcellular localization of TRPM2 determines the fate of cancer cells, apoptosis or survival
Avoiding both the surgically and oncologically futile use of ALPPS
The subtype-specific role of histone H1.0 in cancer cell differentiation and intratumor heterogeneity
Genome-based modeling for adjusting radiotherapy dose (GARD)-a significant step toward the future of personalized radiation therapy
When is KRAS or TP53 mutation predictive of response to immunotherapy for lung cancer?
Mechanisms of the sperm guidance, an essential aid for meeting the oocyte
Hepatopancreaticoduodenectomy for biliary cancer: operative strategies determine near-zero operative mortality, but tumor biology determines an acceptable long-term outcome
Letter to the Editor
Hidden in plain sight: promising therapeutic targets for glioblastoma lurk within DNA damage response pathways
Synthetic lethality vs. synthetic viability due to PARP1 and BRCA2 loss
Differential microRNA expression in epithelial cell populations from human prostate: its relevance to treatment resistance in prostate cancer
How do the QUARTZ trial results inform future research for patients with brain metastases from non-small cell lung cancer?
Treatment approach for large-cell neuroendocrine carcinoma of the lung using next-generation sequencing
This supplement was published without any sponsorship or funding.